Main Content

Business Overview

About Boston Scientific (NYSE: BSX)

We are a growth company conditioned for high performance. Our goal is to create value for shareholders by delivering top tier revenue growth, expanding globally, pursuing operational excellence and investing in a differentiated pipeline of products that improve patients' lives while maintaining our firm commitment to corporate social responsibility.

Our portfolio of devices and therapies help physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.

Our Business

Boston Scientific seeks to consistently grow sales faster than average market revenue growth1 for our target markets, through our strategy of category leadership across our eight business units and diversification into high-growth adjacencies. Our core businesses are organized into two reportable segments, Cardiovascular and MedSurg.

 

Hover state
Cardiology
Hover state
Peripheral Interventions
Graphical presentation of human body
Hover state
Endoscopy
Hover state
Urology
Hover state
Neuromodulation
  • Cardiovascular Businesses
  • MedSurg Businesses

Key growth drivers in the Cardiovascular Segment include:

Our Cardiology business develops and manufactures devices and medical technologies for diagnosing and treating a variety of diseases and abnormalities of the heart.

Our Interventional Cardiology Therapies (ICTx) business focuses on minimally invasive technologies for diagnosing and treating coronary artery disease and aortic valve conditions.

  • The AVVIGO™+ Multi-Modality Guidance System is a streamlined multi-modality guidance system platform that enhances intravascular imaging and physiology experience during percutaneous coronary interventions (PCI).
  • The AGENT™ Drug-Coated Balloon (DCB) is designed to provide a differentiated option for the treatment of in-stent restenosis (ISR) in patients with coronary artery disease.
  • The ACURATE neo2™ Aortic Valve System2 is a self-expanding, supra-annular valve designed to provide effective sealing, placement accuracy, predictable release and expanded patient access for patients with aortic stenosis who are indicated for transcatheter aortic valve replacement (TAVR).
  • The Sentinel™ Cerebral Protection System (CPS) is the first and only commercially available device in the U.S. offering proven embolic protection against TAVR-related stroke risk.
Image of Watchman

 

Our WATCHMAN (WM) business' WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage - the area of the heart where stroke-causing blood clots commonly form.

The next iteration of the device, WATCHMAN™ FLX Pro, is designed with three new features: new HEMOCOATTM Technology to improve the healing process, radiopaque markers for precise device placement and a new larger size for diverse anatomy.

 

Our Cardiac Rhythm Management (CRM) business features implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

  • The EMBLEM™ MRI S-ICD System is the world's first commercially available subcutaneous implantable defibrillator that provides protection from both sudden cardiac death and the risks and complications associated with transvenous leads.
  • The LUX Dx II+™ Insertable Cardiac Monitor System, an insertable monitor for long-term monitoring of arrhythmias associated with conditions such as atrial fibrillation, cryptogenic stroke and syncope.
  • The BodyGuardian™ MINI PLUS Remote Cardiac Monitor, a waterproof, wearable cardiac monitor, provides robust data collection to aid physicians to make a diagnosis.

 

Our Electrophysiology (EP) business is focused on delivering transformative technologies used in the diagnosis and treatment of heart rhythm disorders to better ensure efficient and predictable outcomes.

  • The FARAPULSE™ Pulsed Field Ablation (PFA) System is optimized for patient safety and procedural ease, addressing many risks associated with traditional thermal cardiac ablation and designed to precisely and efficiently ablate cardiac tissue while preserving adjacent tissue.
  • The POLARx™Cryoablation System incorporates physician-driven design changes to provide increased procedural predictability in the treatment of paroxysmal atrial fibrillation.
  • The EP Mapping and Navigation System sets a new bar in high-definition mapping by using three main features (density, resolution and automation) for streamlined targeting and clinical decision-making.
  • The VersaCross Connect™ Access Solution connects industry-leading VersaCross technology with WATCHMAN™, POLARSHEATH™ or FARADRIVE™ sheaths for zero-exchange left heart access.
     

 

Our Peripheral Interventions (PI) business is focused on devices for the diagnosis and minimally invasive treatment of peripheral vascular disease, vessel trauma and cancer.

  • The Drug-Eluting Therapies portfolio is comprised of the Eluvia™ Drug-Eluting Stent and the Ranger™ Drug-Coated Balloon, which were developed for the treatment of peripheral artery disease (PAD).
  • The TheraSphere™ Y-90 Glass Microspheres are a radioembolization treatment for patients diagnosed with liver cancer3. The microspheres are delivered into the hepatic artery to selectively target and destroy tumor cells while minimizing distribution and impact to normal tissue.
  • The Varithena™ Polidocanol Injectable Foam improves the symptoms of superficial venous incompetence and the appearance of varicose veins above and below knee.

 

 

Key growth drivers in the MedSurg Segment include:

 

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with minimally invasive technologies.

  • The AXIOS™ Stent and Electrocautery Enhanced Delivery System offers an endoscopic alternative for transgastric or transduodenal drainage of symptomatic pancreatic pseudocysts and walled-off necrosis – two serious complications of pancreatitis. The AXIOS stent is also indicated for endoscopic drainage of the gallbladder for patients with acute cholecystitis who are at high risk for surgery.
  • The EXALT™ Model D Single-Use Duodenoscope is the first single-use duodenoscope on the market, eliminating the risk of patient-to-patient infection with an out-of-the-box, consistent performance and enabling physicians to complete endoscopic retrograde cholangiopancreatography (ERCP) procedures to diagnose and treat various pancreatic and biliary conditions.
  • The SpyGlass™ DS II Direct Visualization System with Shield Technology enables imaging of the biliary and pancreatic ducts during ERCP and features a complete portfolio of diagnostic and therapeutic tools for biliary stone and stricture management.
  • The OverStitch™ Endoscopic Suturing System and the X-Tack™ Endoscopic HeliX Tacking System provide clinically differentiated technology to enable physicians to close large gastrointestinal defects endoscopically.
  • The Apollo ESG™ System is the first FDA cleared device to perform endoscopic sleeve gastroplasty (ESG) to treat patients who are struggling with obesity.

 

Our Urology business offers comprehensive solutions to support kidney stone removal, prostate health, erectile restoration and urinary continence.


 

Our Neuromodulation (NM) business is committed to developing customized electronic implantable technologies that help patients manage debilitating chronic pain and neurological conditions such as movement disorders.

 

 

References

1 Unless noted otherwise, all references to market segment or sizes, share positions, and growth rates are BSX internal estimates.

2 The ACURATE neo2™ Valve System is an investigational device in the U.S. and not available for sale. CE Marked.

3 In the U.S., TheraSphere is indicated for treatment of hepatocellular carcinoma.

4 Ibrahim A, Elhilali MM, Fahmy N, et al. Double-blinded prospective randomized clinical trial comparing regular and Moses modes of holmium laser lithotripsy. J Endourol. 2020 May;34(5):624-8.

5 Dunne M, Drescher M, Abbott J, et al. MP18-04 Lumenis pulse MOSES technology improves efficiency of laser lithotripsy for patients undergoing mini-PCNL. J Urol. 2021 Sept;206(3)e318. | Boston Scientific calculations for improvement in total operative time & treatment efficiency respectively: 85.9 vs 98.1 min, p=0.03 | 2.4 vs 1.8 mm3/s, p=0.03.

6 Kavoussi NL, Nimmagadda N, Robles J, et al. MOSES technology for holmium laser enucleation of the prostate: A prospective double‐blind randomized control trial. J Urol. 2021 Jul;206(1):104-8.

7 Whiles BB, Martin AJ, Brevik A, et al. Utilization of Moses modulated pulse mode results in improved efficiency in holmium: YAG laser ablation of the prostate. Urology. 2021 Mar;149:187-92.

8 North, James, MD. WHISPER: A Multicenter, Prospective Randomized Controlled Trial Evaluating Subperception SCS at ≤ 1.2 kHz. Presentation at North American Neuromodulation Society (NANS), Las Vegas, NV, January 11-14, 2018. (N=70)

9 The Vercise DBS Lead-Only System (before Stimulator is implanted), the Vercise Gevia System, and the Vercise Genus System are MR Conditional. An MRI examination can be conducted safely when all the instructions in the supplemental manual ImageReady™ MRI Guidelines for Boston Scientific DBS Systems are followed.

 

March 21, 2024

Connect with Boston Scientific Investor Relations

Investor relations contact

300 Boston Scientific Way
Mailstop M405
Marlborough, MA 01752
[email protected]